COMPANY PROFILE

Yuce Biological

Explore full profile

D data management services

Shenzhen, ChinaFounded 2015Biotech & Life Sciences

Valuation $50–100M Last recorded · 2021

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Yuce Biological

Established in 2015, Yuce Biological (Shenzhen Yuce Biotechnology Co., Ltd.) operates as a comprehensive solutions platform for tumor immunotherapy diagnostics and treatment. The company was founded by Dr. Zhibo Gao, who now serves as CEO. Dr. Gao holds a Ph.D. in Medical Science from the Chinese University of Hong Kong and previously served as the Head of the Cancer Bioinformatics Team at BGI, a prominent genomics organization. His background includes significant contributions to the International Cancer Genome Consortium (ICGC) and the Chinese Cancer Genome Consortium (CCGC), with research published in leading scientific journals. This experience in tumor bioinformatics directly informed the company's focus on translating complex genomic research into clinical applications for cancer treatment.

Read full description

Yuce Biological's business model centers on two main pillars: providing clinical testing services for healthcare institutions and offering research and development support for pharmaceutical companies. For its clinical clients, which include over 400 hospitals, the company provides solutions for guiding medication use and dynamically monitoring cancer patients. Its services for more than 30 pharmaceutical enterprises encompass companion diagnostics (CDx) development, biomarker discovery, and central lab services for clinical trials. Revenue is generated through these testing services and collaborative development projects.

The company's core technological strength lies in the detection and analysis of tumor neoantigens, which are proteins that form on cancer cells and can be recognized by the immune system. A key product is the artificial intelligence-based TruNeo® prediction platform, which analyzes tumor exon and transcriptome data to identify these neoantigens. This platform supports the development of personalized cancer vaccines and cell therapies. Yuce Biological also offers a suite of gene detection products, such as YuceOne™ Plus, which assists in guiding immunotherapy, targeted therapy, and chemotherapy decisions. The firm operates a CAP-certified and ISO9001-certified medical laboratory in Shenzhen, equipped with multi-omics platforms for genomics, spatial biology, and pathology analysis. Since its inception, Yuce Biological has completed five funding rounds, securing investments from firms including IDG Capital, to expand its R&D capabilities and market reach.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Shenzhen, China
Employees: 37
Open positions: None listed
Dealroom signal: 26.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Latest news

Press, funding announcements and product moves mentioning Yuce Biological.

See all news

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES COther financing	Nov 2021	$14M	$55M	Tzitzit Aseet	↗
SERIES COther financing	Aug 2020	$43M	$172M	Undisclosed	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Yuce Biological website traffic

Latest recorded traffic for Yuce Biological is 40 monthly website visits, down 90% over the last three months. Yuce Biological's team grew 0% over the past year.

Latest monthly visits40 3-month web change-90% 1-year team growth0%

Monthly website visitsAug 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ENEnvoyaPolymer-Based Nanoparticles for Targeted delivery	Boston, United States	Operational	10	$2M	$8M
TGTongshu GeneA high-tech enterprise that focuses on scientific and technological innovation and focuses on precise molecular diagnosis of tumors	China	Operational
MIMicroMGxThe MGx platform technology, discovers new chemistry by harnessing the power of microbes	Chicago, United States	Operational
BPBio PaletteBio Palette aims to become a world-leading company in the field of microbiome therapeutics by using bacteria optimized by genome editing to modify and control microbiomes	Kobe, Japan	Operational
BIBiospinA biotechnology company developing solutions to protect people from pathogens	Singapore, Singapore	Operational
AVAvantGuardAvantGuard (formerly Halomine) manufactures and supplies high-performance and human-friendly antimicrobial coating materials and technology	Ithaca, United States	Operational
ACActXFocused on making patient genomic information that are useful in everyday medical practice	Seattle, United States	Operational
BIBillionToOneThe only genetic testing platform that accurately and efficiently detects and measures disease at the molecular level	Menlo Park, United States	Operational